A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)
REFRaME-P1
Phase 2 other active
Quick answer
A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML) for Acute Myeloid Leukemia (AML) is a Phase 2 program (other) at SUTRO BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SUTRO BIOPHARMA, INC.
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- other
- Status
- active